Rating disease progression of Friedreich's ataxia by the International Cooperative Ataxia Rating Scale: Analysis of a 603-patient database

Brain

Volumn 136, Issue 1, 2013, Pages 259-268

  Metz, Günther ^a   Coppard, Nicholas ^a   Cooper, Jonathon M ^b   Delatycki, Martin B ^c   Dürr, Alexandra ^d,e   Di Prospero, Nicholas A ^f   Giunti, Paola ^b   Lynch, David R ^g   Schulz, J B ^h   Rummey, Christian ⁱ   Meier, Thomas ^a  

^a Santhera Pharmaceuticals   (Switzerland)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^f NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^g CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^h UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

ⁱ Department of Neurology University Hospital RWTH Aachen and JARA Brain ^*  (Switzerland)

Author keywords

disease progression; Friedreich's ataxia; ICARS; natural history; ratings scale

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BODY POSTURE; CHILD; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; FEMALE; FRIEDREICH ATAXIA; GAIT; HUMAN; INTERNATIONAL COOPERATIVE ATAXIA RATING SCALE; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRIORITY JOURNAL; PSYCHOMETRY; RATING SCALE; SCHOOL CHILD; SENSITIVITY ANALYSIS;

EID: 84873375441     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aws309     Document Type: Article

References (20)

1. Arnold P, Boulat O, Maire R, Kuntzer T. Expanding view of phenotype and oxidative stress in Friedreich's ataxia patients with and without idebenone. Schweiz Arch Neurol Psychiatr 2006; 157: 169-76.
2. Burk K, Malzig U, Wolf S, Heck S, Dimitriadis K, Schmitz-Hubsch T, et al. Comparison of three clinical rating scales in Friedreich ataxia (FRDA). Mov Disord 2009; 24: 1779-84.
3. Cano SJ, Hobart JC, Hart PE, Korlipara LV, Schapira AH, Cooper JM. International Cooperative Ataxia Rating Scale (ICARS): appropriate for studies of Friedreich's ataxia? Mov Disord 2005; 20: 1585-91.
4. Delatycki MB. Evaluating the progression of Friedreich ataxia and its treatment. J Neurol 2009; 256 (Suppl 1): 36-41.
5. Di Prospero NA, Baker A, Jeffries N, Fischbeck KH. Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial. Lancet Neurol 2007; 6: 878-86.
6. Dürr A, Cossee M, Agid Y, Campuzano V, Mignard C, Penet C, et al. Clinical and genetic abnormalities in patients with Friedreich's ataxia. N Engl J Med 1996; 335: 1169-75.
7. Fahey MC, Corben L, Collins V, Churchyard AJ, Delatycki MB. How is disease progress in Friedreich's ataxia best measured? A study of four rating scales. J Neurol Neurosurg Psychiatry 2007; 78: 411-3.
8. Hausse AO, Aggoun Y, Bonnet D, Sidi D, Munnich A, Rotig A, et al. Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia. Heart 2002; 87: 346-9.
9. Lynch DR, Perlman SL, Meier T. A phase 3, double-blind, placebo-controlled trial of idebenone in Friedreich ataxia. Arch Neurol 2010; 67: 941-7.
10. Marelli C, Figoni J, Charles P, Anheim M, Tchikviladze M, Vincitorio CM, et al. Annual change in Friedreich's ataxia evaluated by the Scale for the Assessment and Rating of Ataxia (SARA) is independent of disease severity. Mov Disord 2012; 27: 135-8.
11. Meier T, Perlman SL, Rummey C, Coppard NJ, Lynch DR. Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich's ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study. J Neurol 2012; 259: 284-91.
12. Ribai P, Pousset F, Tanguy ML, Rivaud-Pechoux S, Le Ber I, Gasparini F, et al. Neurological, cardiological, and oculomotor progression in 104 patients with Friedreich ataxia during long-term follow-up. Arch Neurol 2007; 64: 558-64.
13. Santos R, Lefevre S, Sliwa D, Seguin A, Camadro JM, Lesuisse E. Friedreich ataxia: molecular mechanisms, redox considerations, and therapeutic opportunities. Antioxid Redox Signal 2010; 13: 651-90.
14. Schmitz-Hubsch T, Tezenas du Montcel S, Baliko L, Boesch S, Bonato S, Fancellu R, et al. Reliability and validity of the International Cooperative Ataxia Rating Scale: a study in 156 spinocerebellar ataxia patients. Mov Disord 2006; 21: 699-704.
15. Schöls L, Amoiridis G, Przuntek H, Frank G, Epplen JT, Epplen C. Friedreich's ataxia. Revision of the phenotype according to molecular genetics. Brain 1997; 120 (Pt 12): 2131-40.
16. Schulz JB, Boesch S, Burk K, Dürr A, Giunti P, Mariotti C, et al. Diagnosis and treatment of Friedreich ataxia: a European perspective. Nat Rev Neurol 2009; 5: 222-34.
17. Spector PE. Summated rating scale construction: an introduction. Quantitative applications in the social sciences. Vol. 82. Sage Publications Inc.; 1992.
18. Subramony SH, May W, Lynch D, Gomez C, Fischbeck K, Hallett M, et al. Measuring Friedreich ataxia: interrater reliability of a neurologic rating scale. Neurology 2005; 64: 1261-2.
19. Trouillas P, Takayanagi T, Hallett M, Currier RD, Subramony SH, Wessel K, et al. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J Neurol Sci 1997; 145: 205-11.
20. Weidemann F, Rummey C, Bijnens B, Stork S, Jasaityte R, Dhooge J, et al. The heart in Friedreich ataxia: definition of cardiomyopathy, disease severity, and correlation with neurological symptoms. Circulation 2012; 125: 1626-34.